Table 2.
Characteristics | CS (+) CCA (n =95) | CS (-) CCA (n = 272) | p-value |
---|---|---|---|
Age (years) | 62 (56–68) | 65 (58–70) | 0.018 |
Gender, male | 79 (83.2) | 168 (61.8) | <0.001 |
Endemic area | 44 (46.3) | 69 (25.4) | 0.014 |
Diabetes mellitus | 9 (9.5) | 45 (16.5) | 0.09 |
BMI (kg/m2) | 22.8 ± 2.89 | 22.7 ± 2.63 | 0.61 |
HBV infection | 5 (5.3) | 21 (7.7) | 0.42 |
Hepatolithiasis | 3 (3.2) | 35 (12.9) | 0.006 |
CA 19-9 (>37 U/ml) | 60/91 (65.9) | 202/266 (75.9) | 0.074 |
CEA (>5 U/ml) | 21/67 (31.3) | 31/183 (16.9) | 0.021 |
Tumor location | 0.39 | ||
Intrahepatic | 32 (33.7) | 93 (34.2) | |
Perihilar | 38 (40.0) | 90 (33.1) | |
Distal | 25 (26.3) | 89 (32.7) | |
Cancer stage by AJCC, 7th ed. | |||
I, II | 30 (31.6) | 107 (39.5) | 0.36 |
III, IV | 65 (68.4) | 165 (60.5) | |
Treatment intent | |||
Curative intent | 38 (40.0) | 132 (48.7) | 0.14 |
Palliative treatment* | 57 (60.0) | 139 (51.3) | |
Tumor differentiation** | |||
Well/moderate | 38 (73.1) | 112 (68.5) | 0.21 |
Poorly/unknown | 14 (26.9) | 51 (31.3) |
CS, Clonorchis sinensis; CCA, cholangiocarcinoma; CEA, carcinoembryonic antigen; CA 19-9, Carbohydrate antigen 19-9; AJCC, American Joint Committee on Cancer.
Data are expressed as n (%) or median (quartile range) or mean ± SD.
Palliative treatment included R2 resection, radiation therapy, chemotherapy, or only supportive care.
Tumor differentiation was evaluated in 215 patients in whom pathologic analysis was performed.